Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
CPT: Pharmacometrics & Systems Pharmacology
|
August 1, 2024
Automated Poisson regression exposure-response analysis for binary outcomes with PoissonERM
Yuchen Wang, Luke Fostvedt, Jessica Wojciechowski, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 9, 2024
Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogon
Yuchen Wang, Xinyi Pei, Tao Niu, et al.
Clinical Pharmacokinetics
|
January 21, 2022
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
Jessica Wojciechowski, Bimal K Malhotra, Xiaoxing Wang, et al.
British Journal of Clinical Pharmacology
|
March 28, 2022
Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib
Jessica Wojciechowski, Bimal K Malhotra, Xiaoxing Wang, et al.
Clinical Pharmacokinetics
|
February 18, 2022
Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
Jessica Wojciechowski, Bimal K Malhotra, Xiaoxing Wang, et al.
Journal of Clinical Pharmacology
|
May 23, 2020
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies
Daria Stypinski, Luke Fostvedt, Justine L Lam, et al.
Dermatology and Therapy
|
June 19, 2024
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
April W Armstrong, Andrew F Alexis, Andrew Blauvelt, et al.
Clinical Pharmacology in Drug Development
|
August 30, 2024
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure
Luke Fostvedt, Jian Liu, Xiaoxing Wang, et al.
The AAPS Journal
|
March 18, 2018
PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow
Christian Hove Rasmussen, Mike K Smith, Kaori Ito, et al.
Blood Advances
|
January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Daniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
CPT: Pharmacometrics & Systems Pharmacology
|
August 1, 2024
Automated Poisson regression exposure-response analysis for binary outcomes with PoissonERM
Yuchen Wang, Luke Fostvedt, Jessica Wojciechowski, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 9, 2024
Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogon
Yuchen Wang, Xinyi Pei, Tao Niu, et al.
Clinical Pharmacokinetics
|
January 21, 2022
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
Jessica Wojciechowski, Bimal K Malhotra, Xiaoxing Wang, et al.
British Journal of Clinical Pharmacology
|
March 28, 2022
Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib
Jessica Wojciechowski, Bimal K Malhotra, Xiaoxing Wang, et al.
Clinical Pharmacokinetics
|
February 18, 2022
Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
Jessica Wojciechowski, Bimal K Malhotra, Xiaoxing Wang, et al.
Journal of Clinical Pharmacology
|
May 23, 2020
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies
Daria Stypinski, Luke Fostvedt, Justine L Lam, et al.
Dermatology and Therapy
|
June 19, 2024
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
April W Armstrong, Andrew F Alexis, Andrew Blauvelt, et al.
Clinical Pharmacology in Drug Development
|
August 30, 2024
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure
Luke Fostvedt, Jian Liu, Xiaoxing Wang, et al.
The AAPS Journal
|
March 18, 2018
PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow
Christian Hove Rasmussen, Mike K Smith, Kaori Ito, et al.
Blood Advances
|
January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Daniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Page
of 2